The money should carry the new company "for about three years-plus," Worlund said, long enough to get clinical proof of concept with a lead program

Isis has 28 candidates in preclinical and clinical development across a wide variety of indications, with nine scheduled to report data in the next 12 months...Jefferies Group LLC analyst Thomas Wei wrote in a research note that the company is valued entirely on Nuedexta sales, but "we could see upside from new indications and await data from ongoing proof-of-concept studies of AVP-923 in

These data led to Eleven's Phase Ib clinical study of EBI-005 in subjects with dry eye disease, with top-line data from the Phase Ib study expected in the second half of 2013...Portola Pharmaceuticals Inc., of South San Francisco, Calif., reported safety and efficacy data from a Phase II proof-of-concept study of PRT4445 of Eliquis (apixaban) in healthy volunteers

spun out in 2011, and Flexion Therapeutics Inc., of Woburn, Mass., founded by veterans of Eli Lilly and Co.'s Chorus division to advance abandoned early clinical programs through proof of concept. (See BioWorld Today, Feb. 1, 2010, and July 28, 2011.) The $15 million investment in Tacurion will support a Phase II proof-of-concept trial for the drug that should take 18 months to two years to complete

In terms of the in-house programs, in March Galapagos announced positive Phase I data for GLPG0974 in IBD, preparing the ground for a Phase IIa proof of concept study in ulcerative colitis which began last month...The first clinical trials of the drug, GLPG1790, are expected to start within the next year...On Friday, the company's NASDAQ-listed American depository shares (NASDAQ:PRAN) gained 1 cent, closing at $2.27.

GTx Inc., of Memphis, Tenn., said it is starting a proof-of-concept Phase II study to evaluate enobosarm (GTx-024), a selective androgen receptor modulator, in metastatic breast cancer...The primary endpoint is clinical benefit, which will be assessed at six months

Convergence Pharmaceuticals Ltd., of Cambridge, England, started a Phase II proof-of-concept study with CNV2197944 in pain associated with post-herpetic neuralgia (PHN

AG014 comprises oral delivery of an anti-TNF antibody with proven clinical efficacy in IBD, resulting in local efficacy and an improved safety profile over systemic drugs...Additional funding – whether through a second equity tranche or a strategic partnership – will enable the company to move the compounds into proof-of-concept studies...Shares of Northwest (NASDAQ:NWBO) fell 13 cents to close Thursday at $3.77.

Both acute tinnitus and acute hearing loss can be induced in experimental settings, which enables preclinical proof of concept to be established...Proceeds will be used to advance its gene therapy product for congestive heart failure into clinical development

Aeterna Zentaris Inc., of Quebec City, presented updated proof-of-concept results for Disorazol Z cytotoxic conjugates such as AEZS-125 and AEZS-138 in human ovarian and endometrial cancer xenograft models...The study was carried out to explore previous clinical findings with cabozantinib in castration-resistant prostate cancer patients with bone metastases showing a 67 percent rate of bone scan response and other clinical signs of effect

Last month, it inked a deal with AbbVie, of Chicago, giving the big pharma firm an option to RPC4046 following the Phase II proof-of-concept trial in EoE...Funds will be used to progress the clinical development program for lead candidate, Pracinostat, its oral histone deacetylase inhibitor for advanced hematologic malignancies, and for other general corporate purposes...Shares of MEI (NASDAQ:MEIP) closed Friday at $8.35, up 6 cents.

It is the first immune cell clinical trial of its kind in China...A follow-on Phase II trial will include clinical markers of muscle health, levels of utrophin expression and other biomarkers...CALM is investigating the clinical efficacy and safety of Cavatak in Stage IIIc or IV melanoma

The NX03-0040 prostate cancer clinical study of 150 men is testing low (2.5 mg) and high (15 mg) single doses of NX-1207 for the effect to eradicate or shrink low-grade localized prostate cancer tumors...Soricimed Biopharma Inc., of Toronto, reported results from molecular imaging investigation that provided proof of concept for the use of SOR peptides to detect and potentially treat ovarian, breast, thyroid, prostate and colon cancer

Designed to work as a gap junction modifier, the drug has completed Phase I testing, and the planned Phase IIa proof-of-concept trial is expected to include several hundred patients with a heart attack

The Phase I proof-of-concept trial ARMOR1 , part of the ARMOR (Androgen Receptor Modulation Optimized for Response), enrolled 49 patients and was a dose-finding study to evaluate escalating dose levels of galeterone

It will use the proceeds to advance its opthalmic programs through clinical proof of concept

The company is planning to begin clinical studies in the first half of 2014...By that time, in 2014, the company expects to have completed human proof-of-concept studies in each indication

The results from a Phase II study established human proof-of-concept that co-administration of AT2220 just prior to infusing ERT (Myozyme/Lumizyme, or rhGAA enzymes) increases GAA enzyme activity in muscle tissue compared to ERT alone

Critical Pharmaceuticals said that the trial provided proof of concept for the product